The CMTA Inherited Neuropathy Consortium Alliance (CMTA-INC) has enrolled its 10,000th patient, marking a major milestone in the search for treatments...
Your Braces Should Be Earning Their Keep: What a New Study Says About AFOs and CMT
In a new study, Dutch researchers found that AFOs can measurably improve how people with CMT walk, but it depends on how the braces are chosen and fitted.
FDA to Hold Patient Listening Session for CMT2C/TRPV4
This October, the FDA will host a Patient Listening Session for the CMT2C/TRPV4 community, organized by CMTA. During this event, the FDA will hear from people living with this form of CMT about their lives, their needs, and their hopes for new treatments.
Developing an MFN1-Targeted ASO Therapy for CMT2A
CMTA is funding researchers at La Jolla Labs, working with John Svaren, PhD, to develop an ASO treatment that increases MFN1 expression as a potential way to compensate for the damaging effects of MFN2 mutations that cause CMT2A.
CMTA Invests $110,500 in Novel ASO Medicine for CMT2A
The Charcot-Marie-Tooth Association announced a $110,500 investment partnering with La Jolla Labs to develop an antisense oligonucleotide medicine targeting CMT2A, the most common axonal form of CMT, using a novel approach to increase MFN1 expression.
A Backup Gene Offers a New Path to CMT2A Treatment
What if the answer to CMT2A is already in your cells? A new CMTA partnership is testing whether switching on a backup gene could protect nerves when MFN2 fails.
CMTA Invests $165,000 in CMT1A and CMT1E Treatments
CMTA invests $165,000 in University of Iowa research led by Michael Shy, MD, and Robert Piper, PhD, to determine the right time to begin treatment for CMT1A and CMT1E.
Therapeutic Windows and Biomarkers in CMT1A and CMT1E
CMTA-funded researchers are developing new models to define therapeutic windows and identify biomarkers for future CMT1A and CMT1E clinical trials.
When Should Treatment Begin in CMT1A and CMT1E?
What if the timing of treatment could change everything? CMTA is funding a new study to find the optimal window for treating CMT1A and CMT1E; and to discover how to tell if it's working.
Pharmacologic Increase of cGMP for CMT1B/1E Neuropathy
With CMTA support of $225,720, researchers led by Maurizio D’Antonio, PhD, at Ospedale San Raffaele...
